Brokerages Set Pyxis Oncology, Inc. (NASDAQ:PYXS) PT at $9.43

Pyxis Oncology, Inc. (NASDAQ:PYXS) has been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $9.43.

Several analysts have recently weighed in on PYXS shares. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective (down previously from $7.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. Stephens began coverage on shares of Pyxis Oncology in a research report on Friday, November 8th. They set an “overweight” rating and a $13.00 price objective on the stock. William Blair downgraded Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 21st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 target price (down from $10.00) on shares of Pyxis Oncology in a research report on Friday, December 20th.

Pyxis Oncology Stock Performance

Shares of PYXS opened at $1.61 on Tuesday. The firm has a market cap of $95.74 million, a PE ratio of -1.56 and a beta of 1.06. Pyxis Oncology has a 52-week low of $1.49 and a 52-week high of $6.85. The business’s 50 day moving average price is $2.39 and its two-hundred day moving average price is $3.10.

Insiders Place Their Bets

In related news, CFO Pamela Ann Connealy purchased 88,850 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was acquired at an average cost of $1.96 per share, with a total value of $174,146.00. Following the transaction, the chief financial officer now owns 1,199,143 shares of the company’s stock, valued at $2,350,320.28. This represents a 8.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 9.80% of the company’s stock.

Institutional Trading of Pyxis Oncology

Several institutional investors and hedge funds have recently made changes to their positions in PYXS. MetLife Investment Management LLC grew its position in Pyxis Oncology by 41.1% in the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after purchasing an additional 5,484 shares in the last quarter. Pier 88 Investment Partners LLC boosted its stake in shares of Pyxis Oncology by 7.0% in the 3rd quarter. Pier 88 Investment Partners LLC now owns 121,610 shares of the company’s stock worth $446,000 after buying an additional 7,910 shares during the last quarter. Jane Street Group LLC boosted its stake in shares of Pyxis Oncology by 40.8% in the 3rd quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock worth $182,000 after buying an additional 14,349 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Pyxis Oncology in the third quarter valued at approximately $55,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Pyxis Oncology during the third quarter valued at approximately $58,000. Hedge funds and other institutional investors own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.